Immune Thrombocytopenia Purpura Market Expected to Experience Major Growth by 2034, According to DelveInsight | Biotest, Argenx, Sanofi, Principia Biopharma, Rigel Pharma, Principia Biopharma, GSK

The Key Immune Thrombocytopenia Purpura Companies in the market include - Biotest, Argenx, Sanofi/ Principia Biopharma, Rigel Pharmaceuticals, Principia Biopharma, GlaxoSmithKline, Octapharma, Symphogen A/S, Kissei Pharma, Amgen, Jiangsu HengRui Medicine, Genentech, Inc., Bayer, Hoffmann-La Roche, Novartis, PhytoHealth Corporation, and others.
DelveInsight's "Immune Thrombocytopenia Purpura Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Immune Thrombocytopenia Purpura, historical and forecasted epidemiology as well as the Immune Thrombocytopenia Purpura market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Immune Thrombocytopenia Purpura market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Immune Thrombocytopenia Purpura Market Forecast [https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Immune Thrombocytopenia Purpura Market Report:

*
The Immune Thrombocytopenia Purpura market size was valued approximately USD 3,160 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)

*
In 2022, the overall number of cases of immune thrombocytopenia (ITP) in the 7MM was approximately 185,000. It is anticipated that these cases will rise by the year 2032.

*
In 2022, the United States reported the highest incidence of ITP cases, totaling around 66,000 cases. It is projected that these numbers will escalate by the year 2032.

*
In 2022, the United States recorded the highest number of ITP cases, approximately 66,000 in total. Projections indicate that these figures will rise by the year 2032.

*
In the UK, approximately 570 cases of ITP were diagnosed in children, while around 21,500 cases were identified in adults in 2022. It is anticipated that these numbers will rise by 2032.

*
In 2022, the EU4 and the UK collectively represented about 91,600 cases of ITP, constituting roughly half of the total ITP cases in the 7MM.

*
Key Immune Thrombocytopenia Purpura Companies: Biotest, Argenx, Sanofi/ Principia Biopharma, Rigel Pharmaceuticals, Principia Biopharma, GlaxoSmithKline, Octapharma, Symphogen A/S, Kissei Pharma, Amgen, Jiangsu HengRui Medicine, Genentech, Inc., Bayer, Hoffmann-La Roche, Novartis, PhytoHealth Corporation, and others

*
Key Immune Thrombocytopenia Purpura Therapies: BT-595 (IgG Next Generation), Efgartigimod (ARGX-113), Rilzabrutinib(PRN-1008), Fostamatinib disodium, PRN1008, LGD-4665, Octagam 10%, Sym001, R788, Eltrombopag, Romiplostim, Hetrombopag Olamine, Rituxan, Cyclophosphamide, Vincristine, Prednisone, Methylprednisolone and IVIG, rituximab [MabThera/Rituxan], PG2, and others

*
The Immune Thrombocytopenia Purpura epidemiology based on gender analyzed that the majority of cases of ITP are found in females as compared to the male population.

*
The Immune Thrombocytopenia Purpura market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Immune Thrombocytopenia Purpura pipeline products will significantly revolutionize the Immune Thrombocytopenia Purpura market dynamics.

Immune Thrombocytopenia Purpura Overview

Immune Thrombocytopenia Purpura (ITP) is a rare autoimmune disorder where the immune system mistakenly attacks and destroys platelets, which are essential for blood clotting. This leads to low platelet counts, causing symptoms such as easy bruising, prolonged bleeding, petechiae (small red or purple spots on the skin), and in severe cases, internal bleeding. ITP can be either acute, often affecting children, or chronic, more common in adults. Treatment typically focuses on managing symptoms and may include corticosteroids, immunoglobulin therapy, or in some cases, splenectomy.

Get a Free sample for the Immune Thrombocytopenia Purpura Market Report:

https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market [https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Immune Thrombocytopenia Purpura Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Immune Thrombocytopenia Purpura Epidemiology Segmentation:

The Immune Thrombocytopenia Purpura market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

*
Total Prevalence of Immune Thrombocytopenia Purpura

*
Prevalent Cases of Immune Thrombocytopenia Purpura by severity

*
Gender-specific Prevalence of Immune Thrombocytopenia Purpura

*
Diagnosed Cases of Episodic and Chronic Immune Thrombocytopenia Purpura

Download the report to understand which factors are driving Immune Thrombocytopenia Purpura epidemiology trends @ Immune Thrombocytopenia Purpura Epidemiology Forecast [https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Immune Thrombocytopenia Purpura market or expected to get launched during the study period. The analysis covers Immune Thrombocytopenia Purpura market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Immune Thrombocytopenia Purpura Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Immune Thrombocytopenia Purpura Therapies and Key Companies

*
BT-595 (IgG Next Generation): Biotest

*
Efgartigimod (ARGX-113): Argenx

*
Rilzabrutinib(PRN-1008): Sanofi/ Principia Biopharma

*
Fostamatinib disodium: Rigel Pharmaceuticals

*
PRN1008: Principia Biopharma

*
LGD-4665: GlaxoSmithKline

*
Octagam 10%: Octapharma

*
Sym001: Symphogen A/S

*
R788: Kissei Pharma

*
BMS-986004: BMS-986004

*
Eltrombopag: GlaxoSmithKline

*
Romiplostim: Amgen

*
Hetrombopag Olamine: Jiangsu HengRui Medicine

*
Rituxan, Cyclophosphamide, Vincristine, Prednisone: Genentech, Inc.

*
Methylprednisolone and IVIG: Bayer

*
rituximab [MabThera/Rituxan]: Hoffmann-La Roche

*
PG2: PhytoHealth Corporation

Discover more about therapies set to grab major Immune Thrombocytopenia Purpura market share @ Immune Thrombocytopenia Purpura Treatment Market [https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Immune Thrombocytopenia Purpura Market Strengths

*
The increasing number of product launches, coupled with advancements in betterment of existing products will fuel the growth.

*
Higher adaptation and cost-effectiveness of corticosteroid drugs segment will hold the significant share in developed countries

*
Increased acceptance of TPO-RA as a second line of treatment will boost the growth.

*
Rising prevalence of the ITP worldwide and increasing awareness of the disease in the 7MM will drive the market growth during the forecast period.

Immune Thrombocytopenia Purpura Market Opportunities

*
The pipeline of Immune Thrombocytopenia is robust with the involvement of major players, such as BMS, Amgen, Protalex, Squibb,and others.

Scope of the Immune Thrombocytopenia Purpura Market Report

*
Study Period: 2019-2032

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Immune Thrombocytopenia Purpura Companies: Biotest, Argenx, Sanofi/ Principia Biopharma, Rigel Pharmaceuticals, Principia Biopharma, GlaxoSmithKline, Octapharma, Symphogen A/S, Kissei Pharma, Amgen, Jiangsu HengRui Medicine, Genentech, Inc., Bayer, Hoffmann-La Roche, Novartis, PhytoHealth Corporation, and others

*
Key Immune Thrombocytopenia Purpura Therapies: BT-595 (IgG Next Generation), Efgartigimod (ARGX-113), Rilzabrutinib(PRN-1008), Fostamatinib disodium, PRN1008, LGD-4665, Octagam 10%, Sym001, R788, Eltrombopag, Romiplostim, Hetrombopag Olamine, Rituxan, Cyclophosphamide, Vincristine, Prednisone, Methylprednisolone and IVIG, rituximab [MabThera/Rituxan], PG2, and others

*
Immune Thrombocytopenia Purpura Therapeutic Assessment: Immune Thrombocytopenia Purpura current marketed and Immune Thrombocytopenia Purpura emerging therapies

*
Immune Thrombocytopenia Purpura Market Dynamics: Immune Thrombocytopenia Purpura market drivers and Immune Thrombocytopenia Purpura market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Immune Thrombocytopenia Purpura Unmet Needs, KOL's views, Analyst's views, Immune Thrombocytopenia Purpura Market Access and Reimbursement

To know more about Immune Thrombocytopenia Purpura companies working in the treatment market, visit @ Immune Thrombocytopenia Purpura Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Immune Thrombocytopenia Purpura Market Report Introduction

2. Executive Summary for Immune Thrombocytopenia Purpura

3. SWOT analysis of Immune Thrombocytopenia Purpura

4. Immune Thrombocytopenia Purpura Patient Share (%) Overview at a Glance

5. Immune Thrombocytopenia Purpura Market Overview at a Glance

6. Immune Thrombocytopenia Purpura Disease Background and Overview

7. Immune Thrombocytopenia Purpura Epidemiology and Patient Population

8. Country-Specific Patient Population of Immune Thrombocytopenia Purpura

9. Immune Thrombocytopenia Purpura Current Treatment and Medical Practices

10. Immune Thrombocytopenia Purpura Unmet Needs

11. Immune Thrombocytopenia Purpura Emerging Therapies

12. Immune Thrombocytopenia Purpura Market Outlook

13. Country-Wise Immune Thrombocytopenia Purpura Market Analysis (2019-2032)

14. Immune Thrombocytopenia Purpura Market Access and Reimbursement of Therapies

15. Immune Thrombocytopenia Purpura Market Drivers

16. Immune Thrombocytopenia Purpura Market Barriers

17. Immune Thrombocytopenia Purpura Appendix

18. Immune Thrombocytopenia Purpura Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=immune-thrombocytopenia-purpura-market-expected-to-experience-major-growth-by-2034-according-to-delveinsight-biotest-argenx-sanofi-principia-biopharma-rigel-pharma-principia-biopharma-gsk]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada



This release was published on openPR.